Literature DB >> 1336947

Pharmacokinetics and inflammatory fluid penetration of sparfloxacin.

J H Johnson1, M A Cooper, J M Andrews, R Wise.   

Abstract

A single 400-mg oral dose of sparfloxacin was given to each of six healthy male volunteers, and the concentrations of the drug were measured in plasma, cantharides-induced inflammatory fluid, and urine over the subsequent 52 h. The mean peak concentration in plasma of 1.6 micrograms/ml was attained at a mean time of 2.7 h postdose. The mean peak concentration in inflammatory fluid of 1.3 micrograms/ml was attained at a mean time of 5 h postdose. The mean elimination half-life in plasma was 17.6 h, and that in inflammatory fluid was 19.7 h. The overall penetration into inflammatory fluid was 117%. Urinary recovery within the first 52 h postdose was 8.8% of the administered dose. Our results indicate that a once-daily dosage of sparfloxacin should be adequate to treat systemic infections caused by most common bacterial pathogens.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1336947      PMCID: PMC284350          DOI: 10.1128/AAC.36.11.2444

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  8 in total

1.  Drug therapy. Clinical Pharmacokinetics (first of two parts).

Authors:  D J Greenblatt; J Kock-Weser
Journal:  N Engl J Med       Date:  1975-10-02       Impact factor: 91.245

2.  In-vitro activity of sparfloxacin, a new quinolone antimicrobial agent.

Authors:  M A Cooper; J M Andrews; J P Ashby; R S Matthews; R Wise
Journal:  J Antimicrob Chemother       Date:  1990-11       Impact factor: 5.790

3.  Pharmacokinetics and tissue penetration of ciprofloxacin.

Authors:  B Crump; R Wise; J Dent
Journal:  Antimicrob Agents Chemother       Date:  1983-11       Impact factor: 5.191

4.  PHARM--an interactive graphic program for individual and population pharmacokinetic parameter estimation.

Authors:  R Gomeni
Journal:  Comput Biol Med       Date:  1984       Impact factor: 4.589

5.  The influence of protein binding upon tissue fluid levels of six beta-lactam antibiotics.

Authors:  R Wise; A P Gillett; B Cadge; S R Durham; S Baker
Journal:  J Infect Dis       Date:  1980-07       Impact factor: 5.226

6.  The in-vitro activity, pharmacokinetics and tissue penetration of temafloxacin.

Authors:  K Nye; Y G Shi; J M Andrews; J P Ashby; R Wise
Journal:  J Antimicrob Chemother       Date:  1989-09       Impact factor: 5.790

7.  In vitro and in vivo antibacterial activities of AT-4140, a new broad-spectrum quinolone.

Authors:  S Nakamura; A Minami; K Nakata; N Kurobe; K Kouno; Y Sakaguchi; S Kashimoto; H Yoshida; T Kojima; T Ohue
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

8.  In vitro susceptibilities of Coxiella burnetii, Rickettsia rickettsii, and Rickettsia conorii to the fluoroquinolone sparfloxacin.

Authors:  D Raoult; P Bres; M Drancourt; G Vestris
Journal:  Antimicrob Agents Chemother       Date:  1991-01       Impact factor: 5.191

  8 in total
  23 in total

1.  Pharmacokinetics and pharmacodynamics of levofloxacin against Streptococcus pneumoniae and Staphylococcus aureus in human skin blister fluid.

Authors:  A Trampuz; M Wenk; Z Rajacic; W Zimmerli
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

2.  Pharmacokinetics and pharmacodynamics of gatifloxacin against Streptococcus pneumoniae and Staphylococcus aureus in a granulocyte-rich exudate.

Authors:  Andrej Trampuz; Gerd Laifer; Markus Wenk; Zarko Rajacic; Werner Zimmerli
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

3.  Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate.

Authors:  J A Zix; H F Geerdes-Fenge; M Rau; J Vöckler; K Borner; P Koeppe; H Lode
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

Review 4.  Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials.

Authors:  A Aminimanizani; P Beringer; R Jelliffe
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

5.  Spectrometric studies on the sonodynamic damage of protein in the presence of levofloxacin.

Authors:  Bin Liu; Jun Wang; Xin Wang; Bing-Mi Liu; Yu-Mei Kong; Dan Wang; Shu-Kun Xu
Journal:  J Fluoresc       Date:  2010-03-27       Impact factor: 2.217

6.  Pharmacokinetics and inflammatory fluid penetration of clinafloxacin.

Authors:  R Wise; S Jones; I Das; J M Andrews
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

7.  Pharmacokinetics and penetration into inflammatory fluid of trovafloxacin (CP-99,219).

Authors:  R Wise; D Mortiboy; J Child; J M Andrews
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

8.  Signal Detection Between Fluoroquinolone Use and the Risk of Rhegmatogenous Retinal Detachment: Sequence Symmetry Analysis Using Nationwide South Korean Healthcare Database Between 2004 and 2015.

Authors:  Yeon-Hee Baek; Sang Jun Park; Sohyun Jeong; In-Sun Oh; Han Eol Jeong; Kyu Hyung Park; Ju-Young Shin
Journal:  Clin Drug Investig       Date:  2018-12       Impact factor: 2.859

9.  Pharmacokinetics of sparfloxacin in the serum and vitreous humor of rabbits: physicochemical properties that regulate penetration of quinolone antimicrobials.

Authors:  W Liu; Q F Liu; R Perkins; G Drusano; A Louie; A Madu; U Mian; M Mayers; M H Miller
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

10.  Pharmacokinetics of sparfloxacin and serum bactericidal activity against pneumococci.

Authors:  M Trautmann; M Ruhnke; K Borner; J Wagner; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.